Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
Laurence AlbigesToni K Choueiri

Abstract

Monoclonal antibodies that target the programmed death-1 (PD-1)/programmed death-ligand 1(PD-L1) pathway have shown antitumour activity in metastatic renal cell carcinoma (mRCC) and are currently being developed in first-line (in combination) and in previously treated patients. The efficacy targeted therapy (TT) after PD-1/PD-L1 blockade is still unknown. Medical records of mRCC patients treated with investigational PD-1 or PD-L1 inhibitors at 4 academic institutions were reviewed. Patients who received subsequent treatment with TT were selected to collect outcome measures of subsequent TT. Of 99 patients who received PD-1/PD-L1 blockade as part of clinical trials, 56 patients have received subsequent therapy: 44 patients received vascular endothelial growth factor (VEGF)/vascular endothelial growth factor receptor (VEGFR) inhibitors and 12 received mammalian target of rapamycin (mTOR) inhibitors as first subsequent TT. Median follow up, from the start of subsequent TT was 16.1 months (range: 0.2, 30.6 months). TT post PD-1/PD-L1 blockade was administered as second-line, third-line or beyond third-line in 9 (16%), 24 (43%) and 23 patients (41%) respectively. Median time to treatment failure on subsequent TT was 6.6 months (rang...Continue Reading

References

Mar 12, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jennifer S KoJames H Finke
Oct 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel Y C HengToni K Choueiri
Jun 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Julie R BrahmerSuzanne L Topalian
Jan 3, 2012·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E CalvoR A Figlin
Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Jun 5, 2012·The New England Journal of Medicine·Julie R BrahmerJon M Wigginton
Dec 4, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas E HutsonRobert J Motzer
Jan 10, 2014·Cancer Medicine·David F McDermott, Michael B Atkins
Apr 5, 2014·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·D Maxwell ParkinAhmedin Jemal
Sep 19, 2014·World Journal of Gastrointestinal Oncology·Ambedkar Raj Kulandai VeluIlavarasi Sinduja
Dec 7, 2014·Cancer Immunology Research·Lauren C HarshmanToni K Choueiri

❮ Previous
Next ❯

Citations

Jan 19, 2016·Trends in Immunology·Meng Michelle XuYang-Xin Fu
Dec 17, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Lin-Ang WangLin Chen
Nov 29, 2015·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Tim Eisen
Jul 19, 2016·Expert Review of Clinical Immunology·Kathryn E BeckermannJeffrey A Sosman
Aug 5, 2016·British Journal of Cancer·Basma Greef, Tim Eisen
Dec 3, 2016·Therapeutic Advances in Urology·Jose Manuel Ruiz-Morales, Daniel Y C Heng
Aug 31, 2017·Scientific Reports·Fujiang XuDingwei Ye
Nov 9, 2016·Thyroid : Official Journal of the American Thyroid Association·Rong-Liang ShiQing-Hai Ji
Sep 11, 2018·Journal of the European Academy of Dermatology and Venereology : JEADV·C YamashitaK Kabashima
Aug 8, 2017·Current Medicinal Chemistry·Bin LiPingping Chen
Jan 21, 2020·Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology·Shigehiro TsukaharaShuji Hasegawa
Mar 1, 2018·The Oncologist·Nizar M TannirMichael B Atkins
Aug 10, 2020·Current Opinion in Supportive and Palliative Care·Marina DeukerPierre I Karakiewicz
Oct 20, 2017·Molecular and Clinical Oncology·Senji HoshiShoichiro Ohta
Jun 14, 2019·Frontiers in Physiology·Thimios A Mitsiadis
Aug 9, 2020·Medical Oncology·Gianluca PeregoFausto Petrelli
Nov 8, 2020·International Journal of Urology : Official Journal of the Japanese Urological Association·Hiroki IshiharaKazunari Tanabe
Dec 9, 2020·Expert Review of Anticancer Therapy·Melissa BersanelliMimma Rizzo
May 7, 2021·Japanese Journal of Clinical Oncology·Yukari BandoMasato Fujisawa
Aug 16, 2021·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Mike WenzelPierre I Karakiewicz
Jul 1, 2020·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Bradley A McGregorToni K Choueiri

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.